Retargeting of viruses to generate oncolytic agents

Advances in Virology

Volumn 2012, Issue , 2012, Pages

  Verheije, M H ^a   Rottier, P J M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84860861341     PISSN: 16878639     EISSN: 16878647     Source Type: Journal    
DOI: 10.1155/2012/798526     Document Type: Review

References (108)

1. Lech P. J., Russell S. J., Use of attenuated paramyxoviruses for cancer therapy. Expert Review of Vaccines 2010 9 11 1275 1302 2-s2.0-78649391503 10.1586/erv.10.124
2. Barber G. N., Vesicular stomatitis virus as an oncolytic vector. Viral Immunology 2004 17 4 516 527 2-s2.0-11144224896 (Pubitemid 40054231)
3. Thirukkumaran C., Morris D. G., Oncolytic viral therapy using reovirus. Methods in Molecular Biology 2009 542 607 634 2-s2.0-67650296739 10.1007/978-1-59745-561-9-31
4. Hesse A., Kosmides D., Kontermann R. E., Nettelbeck D. M., Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain. Journal of Virology 2007 81 6 2688 2699 2-s2.0-33947389680 10.1128/JVI.02722-06 (Pubitemid 46447034)
5. Rein D. T., Breidenbach M., Wu H., Han T., Haviv Y. S., Wang M., Kirby T. O., Kawakami Y., Dall P., Alvarez R. D., Curiel D. T., Gene transfer to cervical cancer with fiber-modified adenoviruses. International Journal of Cancer 2004 111 5 698 704 2-s2.0-4043092812 10.1002/ijc.20295 (Pubitemid 39062891)
6. Belousova N., Mikheeva G., Gelovani J., Krasnykh V., Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer. Journal of Virology 2008 82 2 630 637 2-s2.0-37849014587 10.1128/JVI.01896-07
7. Poulin K. L., Lanthier R. M., Smith A. C., Christou C., Quiroz M. R., Powell K. L., O'Meara R. W., Kothary R., Lorimer I. A., Parks R. J., Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX. Journal of Virology 2010 84 19 10074 10086 2-s2.0-77956807939 10.1128/JVI.02665-09
8. Waehler R., Russell S. J., Curiel D. T., Engineering targeted viral vectors for gene therapy. Nature Reviews Genetics 2007 8 8 573 587 2-s2.0-34447535345 10.1038/nrg2141 (Pubitemid 47077278)
9. Mathis J. M., Stoff-Khalili M. A., Curiel D. T., Oncolytic adenoviruses-selective retargeting to tumor cells. Oncogene 2005 24 52 7775 7791 2-s2.0-27944445010 10.1038/sj.onc.1209044 (Pubitemid 41670679)
10. Glasgow J. N., Everts M., Curiel D. T., Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Therapy 2006 13 9 830 844 2-s2.0-33747259575 10.1038/sj.cgt.7700928
11. Hall K., Blair Zajdel M. E., Blair G. E., Unity and diversity in the human adenoviruses: exploiting alternative entry pathways for gene therapy. Biochemical Journal 2010 431 3 321 336 2-s2.0-78049287281 10.1042/BJ20100766
12. Nakamura T., Russell S. J., Oncolytic measles viruses for cancer therapy. Expert Opinion on Biological Therapy 2004 4 10 1685 1692 2-s2.0-5644237829 10.1517/14712598.4.10.1685 (Pubitemid 39371764)
13. Hammond A. L., Plemper R. K., Zhang J., Schneider U., Russell S. J., Cattaneo R., Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. Journal of Virology 2001 75 5 2087 2096 2-s2.0-0035121424 10.1128/JVI.75.5.2087-2096.2001 (Pubitemid 32147548)
14. Galanis E., Therapeutic potential of oncolytic measles virus: promises and challenges. Clinical Pharmacology and Therapeutics 2010 88 5 620 625 2-s2.0-77958501444 10.1038/clpt.2010.211
15. Blechacz B., Russell S. J., Measles virus as an oncolytic vector platform. Current Gene Therapy 2008 8 3 162 175 2-s2.0-48249118805 10.2174/156652308784746459
16. Russell S. J., Peng K. W., Measles virus for cancer therapy. Current Topics in Microbiology and Immunology 2009 330 213 241 2-s2.0-58249122672 10.1007/978-3-540-70617-5-11
17. Shah K., Breakefield X. O., HSV amplicon vectors for cancer therapy. Current Gene Therapy 2006 6 3 361 370 2-s2.0-33745217145 10.2174/ 156652306777592063 (Pubitemid 43905452)
18. Campadelli-Fiume G., De Giovanni C., Gatta V., Nanni P., Lollini P. L., Menotti L., Rethinking herpes simplex virus: the way to oncolytic agents. Reviews in Medical Virology 2011 21 4 213 226 10.1002/rmv.691
19. Manservigi R., Argnani R., Marconi P., HSV recombinant vectors for gene therapy. The Open Virology Journal 2010 4 123 156
20. Turrell S. J., Whitehouse A., Mutation of herpesvirus saimiri ORF51 glycoprotein specifically targets infectivity to hepatocellular carcinoma cell lines. Journal of Biomedicine and Biotechnology 2011 2011 14 785158 10.1155/2011/785158
21. Park K., Kim W. J., Cho Y. H., Lee Y. I., Lee H., Jeong S., Cho E. S., Chang S. I., Moon S. K., Kang B. S., Kim Y. J., Cho S. H., Cancer gene therapy using adeno-associated virus vectors. Frontiers in Bioscience 2008 13 7 2653 2659 2-s2.0-38449089618 10.2741/2872 (Pubitemid 351611602)
22. Girod A., Ried M., Wobus C., Lahm H., Leike K., Kleinschmidt J., Deleage G., Hallek M., Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nature Medicine 1999 5 9 1052 1056 2-s2.0-0032728739 (Pubitemid 29439578)
23. Grifman M., Trepel M., Speece P., Gilbert L. B., Arap W., Pasqualini R., Weitzman M. D., Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Molecular Therapy 2001 3 6 964 975 2-s2.0-0034963928 10.1006/mthe.2001.0345 (Pubitemid 32611306)
24. Shi W., Arnold G. S., Bartlett J. S., Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Human Gene Therapy 2001 12 14 1697 1711 2-s2.0-0034814413 10.1089/104303401750476212 (Pubitemid 32911637)
25. Shi W., Bartlett J. S., RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Molecular Therapy 2003 7 4 515 525 2-s2.0-0038027345 10.1016/S1525-0016(03)00042-X (Pubitemid 36553421)
26. Dalba C., Klatzmann D., Logg C. R., Kasahara N., Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors. Current Gene Therapy 2005 5 6 655 667 2-s2.0-29444457742 10.2174/156652305774964659 (Pubitemid 43009509)
27. Tai C. K., Kasahara N., Replication-competent retrovirus vectors for cancer gene therapy. Frontiers in Bioscience 2008 13 8 3083 3095 2-s2.0-38449107235 10.2741/2910 (Pubitemid 351589220)
28. Russell S. J., Cosset F. L., Modifying the host range properties of retroviral vectors. Journal of Gene Medicine 1999 1 5 300 311 2-s2.0-0033182002 (Pubitemid 129631130)
29. Erlwein O., Wels W., Schnierle B. S., Chimeric ecotropic MLV envelope proteins that carry EGF receptor-specific ligands and the Pseudomonas exotoxin a translocation domain to target gene transfer to human cancer cells. Virology 2002 302 2 333 341 2-s2.0-0036438790 10.1006/viro.2002.1517 (Pubitemid 35373861)
30. Chadwick M. P., Morling F. J., Cosset F. L., Russell S. J., Modification of retroviral tropism by display of IGF-I. Journal of Molecular Biology 1999 285 2 485 494 2-s2.0-0033555284 10.1006/jmbi.1998.2350 (Pubitemid 29041786)
31. Pizzato M., Blair E. D., Fling M., Kopf J., Tomassetti A., Weiss R. A., Takeuchi Y., Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells. Gene Therapy 2001 8 14 1088 1096 2-s2.0-0034796426 10.1038/sj.gt.3301494 (Pubitemid 32962706)
32. Guse K., Cerullo V., Hemminki A., Oncolytic vaccinia virus for the treatment of cancer. Expert Opinion on Biological Therapy 2011 11 5 595 608
33. Galmiche M. C., Rindisbacher L., Wels W., Wittek R., Buchegger F., Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting. Journal of General Virology 1997 78, part 11 3019 3027 2-s2.0-0030783171 (Pubitemid 27480842)
34. Paul S., Geist M., Dott K., Snary D., Taylor-Papadimitriou J., Acres B., Silvestre N., Kieny M. P., Balloul J. M., Specific tumor cell targeting by a recombinant MVA expressing a functional single chain antibody on the surface of intracellular mature virus (IMV) particles. Viral Immunology 2007 20 4 664 671 2-s2.0-37549058766 10.1089/vim.2007.0058
35. Kuo L., Godeke G. J., Raamsman M. J., Masters P. S., Rottier P. J., Retargeting of coronavirus by substitution of the spike glycoprotein ectodomain: crossing the host cell species barrier. Journal of Virology 2000 74 3 1393 1406 2-s2.0-0033982337 10.1128/JVI.74.3.1393-1406.2000 (Pubitemid 30044089)
36. Lesch H. P., Kaikkonen M. U., Pikkarainen J. T., Yla-Herttuala S., Avidin-biotin technology in targeted therapy. Expert Opinion on Drug Delivery 2010 7 5 551 564 2-s2.0-77951439766 10.1517/17425241003677749
37. Pereboeva L., Komarova S., Roth J., Ponnazhagan S., Curiel D. T., Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus. Gene Therapy 2007 14 8 627 637 2-s2.0-34247142441 10.1038/sj.gt.3302916 (Pubitemid 46585622)
38. Park J. W., Mok H., Park T. G., Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus. Biochemical and Biophysical Research Communications 2008 366 3 769 774 2-s2.0-37549019328 10.1016/j.bbrc.2007.12.045
39. Henning P., Magnusson M. K., Gunneriusson E., Hong S. S., Boulanger P., Nygren P. A., Lindholm L., Genetic modification of adenovirus 5 tropism by a novel class of ligands based on a three-helix bundle scaffold derived from staphylococcal protein A. Human Gene Therapy 2002 13 12 1427 1439 2-s2.0-0036381953 10.1089/10430340260185067
40. Banerjee P. S., Zuniga E. S., Ojima I., Carrico I. S., Targeted and armed oncolytic adenovirus via chemoselective modification. Bioorganic and Medicinal Chemistry Letters 2011 21 17 4985 4988 10.1016/j.bmcl.2011.05.039
41. Gigout L., Rebollo P., Clement N., Warrington K. H., Muzyczka N., Linden R. M., Weber T., Altering AAV tropism with mosaic viral capsids. Molecular Therapy 2005 11 6 856 865 2-s2.0-18444380824 10.1016/j.ymthe.2005.03.005 (Pubitemid 40724104)
42. Stachler M. D., Chen I., Ting A. Y., Bartlett J. S., Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Molecular Therapy 2008 16 8 1467 1473 2-s2.0-48349091919 10.1038/mt.2008.129
43. Quetglas J. I., Ruiz-Guillen M., Aranda A., Casales E., Bezunartea J., Smerdou C., Alphavirus vectors for cancer therapy. Virus Research 2010 153 2 179 196 2-s2.0-77957282818 10.1016/j.virusres.2010.07.027
44. Ohno K., Sawai K., Lijima Y., Levin B., Meruelo D., Cell-specific targeting of sindbis virus vectors displaying IgG-binding domains of protein A. Nature Biotechnology 1997 15 8 763 767 2-s2.0-0030835821 (Pubitemid 27329479)
45. Klimstra W. B., Williams J. C., Ryman K. D., Heidner H. W., Targeting Sindbis virus-based vectors to Fc receptor-positive cell types. Virology 2005 338 1 9 21 2-s2.0-20644462129 10.1016/j.virol.2005.04.039 (Pubitemid 40835922)
46. Tai C. K., Logg C. R., Park J. M., Anderson W. F., Press M. F., Kasahara N., Antibody-mediated targeting of replication-competent retroviral vectors. Human Gene Therapy 2003 14 8 789 802 2-s2.0-0038021046 10.1089/ 104303403765255174 (Pubitemid 36623515)
47. Douglas J. T., Rogers B. E., Rosenfeld M. E., Michael S. I., Feng M., Curiel D. T., Targeted gene delivery by tropism-modified adenoviral vectors. Nature Biotechnology 1996 14 11 1574 1578 2-s2.0-0029907239 (Pubitemid 26365552)
48. Watkins S. J., Mesyanzhinov V. V., Kurochkina L. P., Hawkins R. E., The "adenobody" approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Therapy 1997 4 10 1004 1012 2-s2.0-0030831076 (Pubitemid 27469929)
49. Miller C. R., Buchsbaum D. J., Reynolds P. N., Douglas J. T., Yancey Gillespie G., Mayo M. S., Raben D., Curiel D. T., Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Research 1998 58 24 5738 5748 2-s2.0-17444427673 (Pubitemid 29006415)
50. Rogers B. E., Douglas J. T., Ahlem C., Buchsbaum D. J., Frincke J., Curiel D. T., Use of a novel cross-linking method to modify adenovirus tropism. Gene Therapy 1997 4 12 1387 1392 2-s2.0-0031453132 (Pubitemid 28004598)
51. Goldman C. K., Rogers B. E., Douglas J. T., Sosnowski B. A., Ying W., Siegal G. P., Baird A., Campain J. A., Curiel D. T., Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Research 1997 57 8 1447 1451 2-s2.0-0030900179 (Pubitemid 27175559)
52. Gu D. L., Gonzalez A. M., Printz M. A., Doukas J., Ying W., D'Andrea M., Hoganson D. K., Curiel D. T., Douglas J. T., Sosnowski B. A., Baird A., Aukerman S. L., Pierce G. F., Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. Cancer Research 1999 59 11 2608 2614 2-s2.0-0033152218 (Pubitemid 29269107)
53. Wickham T. J., Segal D. M., Roelvink P. W., Carrion M. E., Lizonova A., Lee G. M., Kovesdi I., Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. Journal of Virology 1996 70 10 6831 6838 2-s2.0-0029794681 (Pubitemid 26307394)
54. Haisma H. J., Kamps G. K., Bouma A., Geel T. M., Rots M. G., Kariath A., Bellu A. R., Selective targeting of adenovirus to α v β 3 integrins, VEGFR2 and Tie2 endothelial receptors by angio-adenobodies. International Journal of Pharmaceutics 2010 391 1-2 155 161 2-s2.0-77952884036 10.1016/j.ijpharm.2010.02.032
55. Haisma H. J., Pinedo H. M., Rijswijk A., van der Meulen-Muileman I., Sosnowski B. A., Ying W., van Beusechem V. W., Tillman B. W., Gerritsen W. R., Curiel D. T., Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Therapy 1999 6 8 1469 1474 2-s2.0-0032858151 10.1038/sj.gt.3300969 (Pubitemid 29396735)
56. Heideman D. A., Snijders P. J., Craanen M. E., Bloemena E., Meijer C. J. L. M., Meuwissen S. G. M., Van Beusechem V. W., Pinedo H. M., Curiel D. T., Haisma H. J., Gerritsen W. R., Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Therapy 2001 8 5 342 351 2-s2.0-0034917310 10.1038/sj.cgt.7700313 (Pubitemid 32691124)
57. Nettelbeck D. M., Rivera A. A., Kupsch J., Dieckmann D., Douglas J. T., Kontermann R. E., Alemany R., Curiel D. T., Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA. International Journal of Cancer 2004 108 1 136 145 2-s2.0-0345687967 10.1002/ijc.11563 (Pubitemid 37444456)
58. Jongmans W., van den Oudenalder K., Tiemessen D. M., Molkenboer J., Willemsen R., Mulders P. F. A., Oosterwijk E., Targeting of adenovirus to human renal cell carcinoma cells. Urology 2003 62 3 559 565 2-s2.0-0041733307 10.1016/S0090-4295(03)00378-9 (Pubitemid 36999897)
59. Tillman B. W., de Gruijl T. D., Luykx-de Bakker S. A., Scheper R. J., Pinedo H. M., Curiel T. J., Gerritsen W. R., Curiel D. T., Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. Journal of Immunology 1999 162 11 6378 6383 2-s2.0-0033152688 (Pubitemid 29309357)
60. Tillman B. W., Hayes T. L., DeGruijl T. D., Douglas J. T., Curiel D. T., Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Research 2000 60 19 5456 5463 2-s2.0-0034306991
61. Trepel M., Grifman M., Weitzman M. D., Pasqualini R., Molecular adaptors for vascular-targeted adenoviral gene delivery. Human Gene Therapy 2000 11 14 1971 1981 2-s2.0-0034692421 10.1089/10430340050143408
62. Breidenbach M., Rein D. T., Everts M., Glasgow J. N., Wang M., Passineau M. J., Alvarez R. D., Korokhov N., Curiel D. T., Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Therapy 2005 12 2 187 193 2-s2.0-13244298253 10.1038/sj.gt.3302404 (Pubitemid 40185922)
63. Kraaij R., van Rijswijk A. L., Oomen M. H., Haisma H. J., Bangma C. H., Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro. Prostate 2005 62 3 253 259 2-s2.0-12344284722 10.1002/pros.20150 (Pubitemid 40129063)
64. van Zeeburg H. J., van Beusechem V. W., Huizenga A., Haisma H. J., Korokhov N., Gibbs S., Leemans C. R., Brakenhoff R. H., Adenovirus retargeting to surface expressed antigens on oral mucosa. Journal of Gene Medicine 2010 12 4 365 376 2-s2.0-77950889706 10.1002/jgm.1447
65. Li E., Brown S. L., von Seggern D. J., Brown G. B., Nemerow G. R., Signaling antibodies complexed with adenovirus circumvent CAR and integrin interactions and improve gene delivery. Gene Therapy 2000 7 18 1593 1599 2-s2.0-0033781137
66. Yoon S. K., Mohr L., O'Riordan C. R., Lachapelle A., Armentano D., Wands J. R., Targeting a recombinant adenovirus vector to HCC cells using a bifunctional Fab-antibody conjugate. Biochemical and Biophysical Research Communications 2000 272 2 497 504 2-s2.0-0034616659 10.1006/bbrc.2000.2788 (Pubitemid 30444646)
67. Dmitriev I., Kashentseva E., Rogers B. E., Krasnykh V., Curiel D. T., Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. Journal of Virology 2000 74 15 6875 6884 2-s2.0-0033925797 10.1128/JVI.74.15.6875-6884.2000 (Pubitemid 30470671)
68. Wesseling J. G., Bosma P. J., Krasnykh V., Kashentseva E. A., Blackwell J. L., Reynolds P. N., Li H., Parameshwar M., Vickers S. M., Jaffee E. M., Huibregtse K., Curiel D. T., Dmitriev I., Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Therapy 2001 8 13 969 976 2-s2.0-0034933606 10.1038/sj.gt.3301473 (Pubitemid 32633373)
69. Ebbinghaus C., Al-Jaibaji A., Operschall E., Schoffel A., Peter I., Greber U. F., Hemmi S., Functional and selective targeting of adenovirus to high-affinity Fc γ receptor I-positive cells by using a bispecific hybrid adapter. Journal of Virology 2001 75 1 480 489 2-s2.0-0034749754 10.1128/JVI.75.1.480-489.2001
70. Kashentseva E. A., Seki T., Curiel D. T., Dmitriev I. P., Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Research 2002 62 2 609 616 2-s2.0-0037081279 (Pubitemid 34106439)
71. Li H. J., Everts M., Pereboeva L., Komarova S., Idan A., Curiel D. T., Herschman H. R., Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anticarcinoembryonic antigen bispecific adapter. Cancer Research 2007 67 11 5354 5361 2-s2.0-34347206848 10.1158/0008-5472.CAN-06-4679 (Pubitemid 46997275)
72. Green N. K., Morrison J., Hale S., Briggs S. S., Stevenson M., Subr V., Ulbrich K., Chandler L., Mautner V., Seymour L. W., Fisher K. D., Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. Journal of Gene Medicine 2008 10 3 280 289 2-s2.0-40549116345 10.1002/jgm.1121 (Pubitemid 351359640)
73. Moselhy J., Sarkar S., Chia M. C., Mocanu J. D., Taulier N., Liu F. F., Wu X. Y., Evaluation of copolymers of N-isopropylacrylamide and 2-dimethyl(aminoethyl)methacrylate in nonviral and adenoviral vectors for gene delivery to nasopharyngeal carcinoma. International Journal of Nanomedicine 2007 2 3 461 478 2-s2.0-38449089429 (Pubitemid 350047789)
74. Han J., Zhao D., Zhong Z., Zhang Z., Gong T., Sun X., Combination of adenovirus and cross-linked low molecular weight PEI improves efficiency of gene transduction. Nanotechnology 2010 21 10 2-s2.0-77149154950 10.1088/0957-4484/ 21/10/105106 105106
75. Bachtarzi H., Stevenson M., Subr V., Ulbrich K., Seymour L. W., Fisher K. D., Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins. Journal of Controlled Release 2011 150 2 196 203 10.1016/j.jconrel.2010.10.011
76. Fisher K. D., Green N. K., Hale A., Subr V., Ulbrich K., Seymour L. W., Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy. Journal of Drug Targeting 2007 15 7-8 546 551 2-s2.0-34547697008 10.1080/10611860701501014 (Pubitemid 47209055)
77. Stevenson M., Hale A. B., Hale S. J., Green N. K., Black G., Fisher K. D., Ulbrich K., Fabra A., Seymour L. W., Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via α 6-integrins. Cancer Gene Therapy 2007 14 4 335 345 2-s2.0-33947242506 10.1038/sj.cgt.7701022 (Pubitemid 46425781)
78. Lanciotti J., Song A., Doukas J., Sosnowski B., Pierce G., Gregory R., Wadsworth S., O'Riordan C., Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Molecular Therapy 2003 8 1 99 107 2-s2.0-0042199037 10.1016/S1525-0016(03)00139-4 (Pubitemid 36939301)
79. Eto Y., Gao J. Q., Sekiguchi F., Kurachi S., Katayama K., Maeda M., Kawasaki K., Mizuguchi H., Hayakawa T., Tsutsumi Y., Mayumi T., Nakagawa S., PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. Journal of Gene Medicine 2005 7 5 604 612 2-s2.0-21144468804 10.1002/jgm.699 (Pubitemid 40744526)
80. Gao J. Q., Eto Y., Yoshioka Y., Sekiguchi F., Kurachi S., Morishige T., Yao X., Watanabe H., Asavatanabodee R., Sakurai F., Mizuguchi H., Okada Y., Mukai Y., Tsutsumi Y., Mayumi T., Okada N., Nakagawa S., Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. Journal of Controlled Release 2007 122 1 102 110 2-s2.0-34548020561 10.1016/j.jconrel.2007.06.010 (Pubitemid 47284554)
81. Jung Y., Park H. J., Kim P. H., Lee J., Hyung W., Yang J., Ko H., Sohn J. H., Kim J. H., Huh Y. M., Yun C. O., Haam S., Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells. Journal of Controlled Release 2007 123 2 164 171 2-s2.0-35348835660 10.1016/j.jconrel.2007.08.002 (Pubitemid 47570000)
82. Chen C. Y., May S. M., Barry M. A., Targeting adenoviruses with factor X-single-chain antibody fusion proteins. Human Gene Therapy 2010 21 6 739 749 2-s2.0-77954986093 10.1089/hum.2009.190
83. Bartlett J. S., Kleinschmidt J., Boucher R. C., Samulski R. J., Targeted adeno-associated virus vector transduction of nonpermissive cells mediated cells by a bispecific F(ab' γ)2 antibody. Nature Biotechnology 1999 17 2 181 186 2-s2.0-0032892684 (Pubitemid 29072544)
84. Nakano K., Asano R., Tsumoto K., Kwon H., Goins W. F., Kumagai I., Cohen J. B., Glorioso J. C., Herpes simplex virus targeting to the EGF receptor by a gD-Specific soluble bridging molecule. Molecular Therapy 2005 11 4 617 626 2-s2.0-14844359145 10.1016/j.ymthe.2004.12.012 (Pubitemid 40353119)
85. Bian H., Fournier P., Moormann R., Peeters B., Schirrmacher V., Selective gene transfer in vitro to tumor cells via recombinant newcastle disease virus. Cancer Gene Therapy 2005 12 3 295 303 2-s2.0-14644423954 10.1038/sj.cgt.7700774 (Pubitemid 40315189)
86. Bian H., Wilden H., Fournier P., Peeters B., Schirrmacher V., In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein. International Journal of Oncology 2006 29 6 1359 1369 2-s2.0-39049178459
87. Haijema B. J., Volders H., Rottier P. J., Switching species tropism: an effective way to manipulate the feline coronavirus genome. Journal of Virology 2003 77 8 4528 4538 2-s2.0-0037384422 10.1128/JVI.77.8.4528-4538.2003 (Pubitemid 36402803)
88. Wurdinger T., Verheije M. H., Raaben M., Bosch B. J., de Haan C. A. M., van Beusechem V. W., Rottier P. J. M., Gerritsen W. R., Targeting non-human coronaviruses to human cancer cells using a bispecific single-chain antibody. Gene Therapy 2005 12 18 1394 1404 2-s2.0-29744436387 10.1038/sj.gt.3302535 (Pubitemid 43090389)
89. Wurdinger T., Verheije M. H., Broen K., Bosch B. J., Haijema B. J., De Haan C. A. M., Van Beusechem V. W., Gerritsen W. R., Rottier P. J. M., Soluble receptor-mediated targeting of mouse hepatitis coronavirus to the human epidermal growth factor receptor. Journal of Virology 2005 79 24 15314 15322 2-s2.0-29744449337 10.1128/JVI.79.24.15314-15322.2005 (Pubitemid 43032313)
90. Verheije M. H., Lamfers M. L., Wurdinger T., Grinwis G. C., Gerritsen W. R., Van Beusechem V. W., Rottier P. J., Coronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastoma. Journal of Virology 2009 83 15 7507 7516 2-s2.0-67650885885 10.1128/JVI.00495-09
91. Hemminki A., Dmitriev I., Liu B., Desmond R. A., Alemany R., Curiel D. T., Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Research 2001 61 17 6377 6381 2-s2.0-0035418580 (Pubitemid 32783241)
92. van Beusechem V. W., Mastenbroek D. C., van den Doel P. B., Lamfers M. L. M., Grill J., Wurdinger T., Haisma H. J., Pinedo H. M., Gerritsen W. R., Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gene Therapy 2003 10 23 1982 1991 2-s2.0-0242287933 10.1038/sj.gt.3302103 (Pubitemid 37337074)
93. Carette J. E., Graat H. C., Schagen F. H., Mastenbroek D. C., Rots M. G., Haisma H. J., Groothuis G. M., Schaap G. R., Bras J., Kaspers G. J., Wuisman P. I., Gerritsen W. R., van Beusechem V. W., A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor. Virology 2007 361 1 56 67 2-s2.0-34047271091 10.1016/j.virol.2006.11.011 (Pubitemid 46551227)
94. Einfeld D. A., Schroeder R., Roelvink P. W., Lizonova A., King C. R., Kovesdi I., Wlckham T. J., Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. Journal of Virology 2001 75 23 11284 11291 2-s2.0-0035158631 10.1128/JVI.75.23.11284-11291.2001 (Pubitemid 33063218)
95. Hemminki A., Wang M., Hakkarainen T., Desmond R. A., Wahlfors J., Curiel D. T., Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential. Cancer Gene Therapy 2003 10 8 583 588 2-s2.0-0041732080 10.1038/sj.cgt.7700606 (Pubitemid 36988532)
96. Glasgow J. N., Mikheeva G., Krasnykh V., Curiel D. T., A strategy for adenovirus vector targeting with a secreted single chain antibody. Plos One 2009 4 12 e8355 2-s2.0-77949536402
97. Van Beusechem V. W., Grill J., Jeroen Mastenbroek D. C., Wickham T. J., Roelvink P. W., Haisma H. J., Lamfers M. L. M., Dirven C. M. F., Pinedo H. M., Gerritsen W. R., Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. Journal of Virology 2002 76 6 2753 2762 2-s2.0-0036187968 10.1128/JVI.76.6.2753-2762.2002 (Pubitemid 34184861)
98. Barker S. D., Dmitriev I. P., Nettelbeck D. M., Liu B., Rivera A. A., Alvarez R. D., Curiel D. T., Hemminki A., Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma. Gene Therapy 2003 10 14 1198 1204 2-s2.0-0041308272 10.1038/sj.gt.3301974 (Pubitemid 36896595)
99. Everts M., Kim-Park S. A., Preuss M. A., Passineau M. J., Glasgow J. N., Pereboev A. V., Mahasreshti P. J., Grizzle W. E., Reynolds P. N., Curiel D. T., Selective induction of tumor-associated antigens in murine pulmonary vasculature using double-targeted adenoviral vectors. Gene Therapy 2005 12 13 1042 1048 2-s2.0-21744431697 10.1038/sj.gt.3302491 (Pubitemid 40946146)
100. Li H. J., Everts M., Yamamoto M., Curiel D. T., Herschman H. R., Combined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumors. Cancer Research 2009 69 2 554 564 2-s2.0-58349088725 10.1158/0008-5472.CAN-08- 3209
101. Reynolds P. N., Nicklin S. A., Kaliberova L., Boatman B. G., Grizzle W. E., Balyasnikova I. V., Baker A. H., Danilov S. M., Curiel D. T., Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nature Biotechnology 2001 19 9 838 842 2-s2.0-0034861664 10.1038/nbt0901-838 (Pubitemid 32816753)
102. Reynolds P. N., Zinn K. R., Gavrilyuk V. D., Balyasnikova I. V., Rogers B. E., Buchsbaum D. J., Wang M. H., Miletich D. J., Grizzle W. E., Douglas J. T., Danilov S. M., Curiel D. T., A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Molecular Therapy 2000 2 6 562 578 2-s2.0-0034577049 10.1006/mthe.2000.0205
103. Verheije M. H., Wurdinger T., van Beusechem V. W., de Haan C. A., Gerritsen W. R., Rottier P. J., Redirecting coronavirus to a nonnative receptor through a virus-encoded targeting adapter. Journal of Virology 2006 80 3 1250 1260 10.1128/JVI.80.3.1250-1260.2006 (Pubitemid 43134082)
104. de Haan C. A., van Genne L., Stoop J. N., Volders H., Rottier P. J., Coronaviruses as vectors: position dependence of foreign gene expression. Journal of Virology 2003 77 21 11312 11323 2-s2.0-0142124183 10.1128/JVI.77.21.11312-11323.2003 (Pubitemid 37271630)
105. Kimball K. J., Preuss M. A., Barnes M. N., Wang M., Siegal G. P., Wan W., Kuo H., Saddekni S., Stockard C. R., Grizzle W. E., Harris R. D., Aurigemma R., Curiel D. T., Alvarez R. D., A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clinical Cancer Research 2010 16 21 5277 5287 2-s2.0-78049468477 10.1158/1078-0432.CCR-10-0791
106. Koppers-Lalic D., Hoeben R. C., Non-human viruses developed as therapeutic agent for use in humans. Reviews in Medical Virology 2011 21 4 227 239 10.1002/rmv.694
107. Green N. K., Herbert C. W., Hale S. J., Hale A. B., Mautner V., Harkins R., Hermiston T., Ulbrich K., Fisher K. D., Seymour L. W., Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Therapy 2004 11 16 1256 1263 2-s2.0-4444374585 10.1038/sj.gt.3302295 (Pubitemid 39173432)
108. Nakashima H., Kaur B., Chiocca E. A., Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine and Growth Factor Reviews 2010 21 2-3 119 126 2-s2.0-77953537092 10.1016/j.cytogfr.2010.02.004